Related Experiment Video

Updated: Sep 10, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

[Perinatal corticotherapy: updates]

I Hamon1, J M Hascoet

  • 1Soins Intensifs et Réanimation Néonatals, Maternité Régionale Universitaire de Nancy, 10, rue du Dr Heydenreich, 54042 Nancy.

Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
|March 9, 2002
PubMed

Insights

Antenatal corticosteroid treatment improves lung function in premature infants, reducing respiratory distress. Careful evaluation of treatment courses and steroid type (betamethasone preferred) is crucial to maximize benefits and minimize side effects.

Area of Science:

  • Neonatal Medicine
  • Pulmonology
  • Pharmacology

Context:

  • Antenatal corticosteroid therapy is established for fetal lung maturation.
  • Postnatal corticosteroid use benefits neonates with chronic lung disease.
  • Optimal treatment protocols require further refinement.

Purpose:

  • To review recent data on antenatal and postnatal corticosteroid use.
  • To suggest an updated treatment policy for improved neonatal outcomes.
  • To address remaining questions regarding efficacy and safety.

Summary:

  • Antenatal corticosteroids significantly reduce severe respiratory distress syndrome (RDS) risk, with benefits observed as early as 23 weeks gestation.
  • Treatment efficacy is linked to gestational age and number of courses; benefits may be outweighed by side effects after 3 courses.
  • Betamethasone is favored over dexamethasone due to a lower risk of neurological complications. Postnatal use is reserved for severe chronic lung disease, with pulse therapy as the preferred method.

Impact:

  • Updated treatment policies can improve the prognosis for premature infants.
  • Evidence supports the preferential use of betamethasone for antenatal and postnatal corticosteroid therapy.
  • Optimizing treatment intervals and administration methods (pulse therapy) can enhance safety and efficacy.

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

A Preterm Rat Model for Pain Studies01:37

A Preterm Rat Model for Pain Studies

Published on: February 9, 2024

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...